Astrazeneca tagrisso patent expiry?

Patent expiry for Tagrisso (osimertinib) isn’t a single date. There are multiple patent families (the compound itself, salts/formulations, and methods of use), and expiries vary by country and can be extended by patent-term adjustments and regulatory exclusivities.

High‑level points:
- Core compound and related patents: expiry dates depend on the jurisdiction and any term extensions. In major markets these often fall roughly in the late 2020s to early 2030s range, but can be pushed later by adjustments.
- Formulation, salt, and method‑of‑use patents: these can extend protection further in some territories.
- Regulatory exclusivities: data exclusivity (e.g., 5 years in the US for a new chemical entity, plus possible pediatric exclusivity) can delay generic entry even after patent expiry.
- Supplementary Protection Certificates (SPCs) in Europe can extend protection beyond the basic expiry by up to about 5 years in some cases.

Because exact dates are jurisdiction-specific, the best approach is to check the patent families in the target region.

If you want, tell me:
- Which jurisdictions you care about (US, EU, UK, Japan, etc.)
- Whether you want only the composition‑of‑matter patents or also use/formulation patents

I can then look up current expiry dates for those specific patent families and provide a concise summary with sources.